Amphiphilic Peptides for Efficient siRNA Delivery by Mozaffari, Saghar et al.
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
4-17-2019
Amphiphilic Peptides for Efficient siRNA Delivery
Saghar Mozaffari
Chapman University, mozaf100@mail.chapman.edu
Emira Bousoik
Chapman University, bouso100@mail.chapman.edu
Farideh Amirrad
Chapman University, amirr100@mail.chapman.edu
Robert Lamboy
Chapman University, robertlamboy@gmail.com
Melissa Coyle
Chapman University, coyle109@mail.chapman.edu
See next page for additional authors
Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Cancer Biology Commons, Cell
Anatomy Commons, Cell Biology Commons, Medicinal and Pharmaceutical Chemistry Commons,
Other Cell and Developmental Biology Commons, and the Other Pharmacy and Pharmaceutical
Sciences Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Mozaffari S, Bousoik E, Amirrad F, et al. Amphiphilic peptides for efficient siRNA delivery. Polymers. 2019;11:703. doi: 10.3390/
polym11040703
Amphiphilic Peptides for Efficient siRNA Delivery
Comments
This article was originally published in Polymers, volume 11, in 2019. DOI: 10.3390/polym11040703
Creative Commons License
Creative
Commons
License
This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright
The authors
Authors
Saghar Mozaffari, Emira Bousoik, Farideh Amirrad, Robert Lamboy, Melissa Coyle, Ryley Hall, Abdulaziz
Alasmari, Parvin Mahdipoor, Keykavous Parang, and Hamidreza Montazeri Aliabadi
This article is available at Chapman University Digital Commons: https://digitalcommons.chapman.edu/pharmacy_articles/642
polymers
Article
Amphiphilic Peptides for Efficient siRNA Delivery
Saghar Mozaffari, Emira Bousoik , Farideh Amirrad, Robert Lamboy, Melissa Coyle ,
Ryley Hall , Abdulaziz Alasmari, Parvin Mahdipoor, Keykavous Parang * and
Hamidreza Montazeri Aliabadi *
Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences,
Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA 92618,
USA; mozaf100@mail.chapman.edu (S.M.); bouso100@mail.chapman.edu (E.B.);
amirr100@mail.chapman.edu (F.A.); robertlamboy@gmail.com (R.L.); coyle109@mail.chapman.edu (M.C.);
hall222@mail.chapman.edu (R.H.); alasm103@mail.chapman.edu (A.A.); mahdi102@mail.chapman.edu (P.M.)
* Correspondence: parang@chapman.edu (K.P.); montazer@chapman.edu (H.M.A.)
Received: 10 January 2019; Accepted: 12 April 2019; Published: 17 April 2019


Abstract: A number of amphiphilic cyclic peptides—[FR]4, [WR]5, and [WK]5—containing
hydrophobic and positively-charged amino acids were synthesized by Fmoc/tBu solid-phase peptide
methods and evaluated for their efficiency in intracellular delivery of siRNA to triple-negative
breast cancer cell lines, MDA-MB-231 and MDA-MB-468, in the presence and absence of
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Among the peptides, [WR]5, which contains
alternate tryptophan (W) and arginine (R) residues, was found to be the most efficient in the delivery
of siRNA by improving the delivery by more than 3-fold when compared to other synthesized cyclic
peptides that were not efficient. The data also showed that co-formulation of [WR]5 with lipid DOPE
significantly enhanced the efficiency of siRNA delivery by up to ~2-fold compared to peptide alone.
Based on the data indicating the efficiency of [WR]5 in siRNA delivery, peptides containing arginine
residues on the ring and tryptophan residues on the side chain, [R6K]W6 and [R5K]W5, were also
evaluated, and demonstrated improved delivery of siRNA. The presence of DOPE again enhanced the
siRNA delivery in most cases. [WR]5, [R5K]W5, and [R6K]W6 did not show any significant toxicity in
MDA-MB-231, MDA-MB-468, and AU565 WT cells at N/P ratios of 20:1 or less, in the presence and
absence of DOPE. Silencing of kinesin spindle protein (KSP) and Janus kinase 2 (JAK2) was evaluated
in MDA-MB-231 cells in the presence of the peptides. The addition of DOPE significantly enhanced
the silencing efficiency for all selected peptides. In conclusion, peptides containing tryptophan and
arginine residues were found to enhance siRNA delivery and to generate silencing of targeted proteins
in the presence of DOPE.
Keywords: siRNA; peptides; breast cancer; hydrophobic modification; cell internalization
1. Introduction
Post-transcriptional regulation of protein expression is an important intracellular mechanism that
relies on the interference of non-coding RNAs (RNAi) and a protein complex containing Argonaute
protein (AGO) and cofactors [1]. Human AGO protein subfamily consists of AGO1, 2, 3, and 4 and
bind to microRNAs (miRNAs) and small interfering RNAs (siRNAs) [2]. siRNA would lose one of
the strands (known as passenger strand), and the guide strand is incorporated into AGO-containing
protein complex (known as RNA-induced silencing complex or RISC). The guide strand directs the
RISC complex to the target mRNA, and the binding of the guide strand to the mRNA (based on
complementary sequences) will trigger the cleavage and therefore, degradation of mRNA, which is
known as “silencing” [3]. This intracellular mechanism has been the inspiration for different exogenous
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small RNA interfering strategies for protein silencing. However, delivering nucleic acids into the cell is
challenging due to their size, hydrophilic nature, and the negative charges created by phosphate groups.
Throughout the last two decades, efficient non-viral siRNA delivery strategies have been pursued,
which include different physical approaches [4]. Physical approaches such as electro-permeabilization
and microinjection have been utilized in the delivery of siRNA. The use of physical strategies can be
highly effective in siRNA delivery to a small population of cells [5]; however, these approaches can
jeopardize the integrity of cellular membrane and are restricted as in vitro investigational tools [6].
Therefore, molecular carriers such as peptide-, polymer-, and lipid-based strategies have been
investigated for in vivo siRNA delivery.
One of the recent attempts in siRNA delivery is a multi-component approach known as stable
nucleic acid-lipid particles (SNALPs). This approach was originally adapted from a DNA delivery
protocol and is based on encapsulating the nucleic acid cargo into lipid-based liposomal-like particles
with a less than 200 nm diameter [7]. This approach was first reported for targeting hepatitis B virus in
a mouse model [8], and has since been studied in clinical trials (Phases I and II) for targeting polo-like
kinase I (PLK1) in patients in with adrenocortical cancer [9]. Additionally, direct conjugation of
N-acetylgalactosamine (GalNAc; a targeting moiety with high affinity for the asialoglycoprotein
receptor in the liver) to siRNA or incorporating it into the siRNA delivery system has been
recently reported [10]. Polyelectrolyte-gold nanoassemblies [11], polycation liposome-encapsulated
calcium phosphate nanoparticles [12], folic acid-modified mesoporous silica nanocarriers [13],
and folate-PEG-appended dendrimer/α-cyclodextrin conjugates [14,15] are among other recently
reported strategies for siRNA delivery.
Cell-penetrating peptides (CPPs) have drawn significant attention in the drug delivery field.
The intrinsic property of CPPs to deliver therapeutic molecules (nucleic acids, drugs, imaging agents)
to cells and tissues in a nontoxic manner has indicated that they may be beneficial for enhancing the
cellular delivery of drugs and diagnostic agents with limited cellular uptake [16]. The CPPs have been
widely used in molecular pharmaceutics, due to their ability to increase cellular internalization and to
alter the pharmacokinetic pattern of the drug [17]. The modification of CPPs is required to act as a
delivery vector for siRNA to minimize the degradation and mediate the efficient cellular uptake.
We have previously reported several cyclic peptides with cell penetrating properties [18–21].
The linear peptides are usually more susceptible to hydrolysis by peptidases when compared with
the cyclic peptides. Furthermore, the cellular uptake of many linear cell-penetrating peptides
occurs predominantly through an endocytic pathway. On the other hand, cyclic peptides containing
alternate tryptophan and arginine residues [WR]5 and [WR]4, and the corresponding peptide-capped
gold nanoparticles were found to act as efficient molecular transporters of siRNA in human cervix
adenocarcinoma (HeLa) cells. The mechanism of uptake for [WR]4 and [WR]5 was found to be
endocytosis independent, since no significant difference in cellular uptake was observed in the presence
of different endocytic inhibitors [18]. Flow cytometry studies showed that [WR]5 and [WR]5-capped
gold nanoparticles improved the intracellular uptake of siRNA by about 2- and 3.8-fold versus siRNA
alone. We also found out that both delivery platforms were less toxic when compared to lipofectamine.
Fluorescence microscopy data confirmed the localization of fluorescence-labeled siRNA in cytoplasm
in the presence of [WR]5 and [WR]5-capped gold nanoparticles [22]. Thus, we hypothesized that the
positively charged residues on the peptide can have electrostatic interactions with negatively charged
phosphate residues in the phospholipid bilayer and siRNA. Furthermore, the hydrophobic tryptophan
groups could interact with hydrophobic residues in the lipid membrane.
Herein, we investigated [WR]5 in comparison with other cyclic peptides containing alternate
hydrophobic and positively-charged residues, [FR]4 and [WK]5. The rationale of this design is based on
the preliminary data that cyclic peptide [WR]5 containing alternative tryptophan (W) and arginine (R)
residues significantly enhanced the cellular of negatively charged phosphopeptides [20] and siRNA [22].
Furthermore, we compared the siRNA delivery with cyclic peptides containing arginine residues
attached with a hydrophobic chain of tryptophan [R5K]W5, and [R6K]W6. The peptides were used
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alone or in different ratios with siRNA for comparative studies in two triple-negative breast cancer cell
lines (MDA-MB-231 and MDA-MB-468) for cyclic peptides and an additional breast cancer cell line
(AU565) for [R5K]W5 and [R6K]W6.
Furthermore, we have evaluated the effect of addition of 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) to the delivery system. Enhancing the level of interaction with
lipophilic moieties of cell membrane by increasing the hydrophobic characteristics of the carrier has
been a well-studied strategy in delivering nucleic acid to cytoplasm. We have previously reported
using DOPE as an additional hydrophobic component for hybrid peptides. In 2017, we reported siRNA
delivery to breast cancer cell lines using arginine and lysine-containing linear and cyclic peptides
conjugated to a variety of fatty acids to enhance the hydrophobicity of the carrier. Our experiments
showed a significant improvement in cell internalization and silencing efficiency of the siRNA after
addition of DOPE to the delivery system [23]. Finally, silencing efficiency of the selected peptides was
investigated for kinesin spindle protein (KSP), and Janus kinase 2 (JAK2) proteins in MDA-MB-231 cells.
2. Materials and Methods
2.1. Materials
All amino acids and resins were purchased from AAPPTec (Louisville, KY, USA) for in-house
peptide synthesis. All the other chemicals and reagents used in synthesis and purification of peptides,
as well as TRIzol reagent and formaldehyde (37%) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was obtained from Avanti Polar
Lipids Inc. (Alabaster, AL, USA). The chemical structures of the final products were confirmed
by high-resolution matrix-assisted laser desorption/ionization (MALDI) time-of-flight (MALDI-TOF,
GT 0264) from Bruker Inc. (Billerica, MA, USA). Mass spectra were collected using a freshly prepared
α-cyano-4-hydroxycinnamic acid (5 mg/mL) in water (0.1% TFA) and acetonitrile (0.1% TFA) in a 1:1
ration (v/v) as the matrix that was mixed with the peptides before the measurement. Hanks’ Balanced
Salt Solution (HBSS), fetal bovine serum (FBS), penicillin (10,000 U/mL), and streptomycin (10 mg/mL),
and SYBR Green II were provided by Life Technologies (Grand Island, NY, USA). iScriptTM Reverse
transcription Supermix and iTaq Universal SYBR Green Supermix used in qPCR, as well as all western
blot accessories (including 10% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Clarity™ Western
ECL Substrate, Trans-blot® TurboTM Cassettes, and Trans-Blot® Turbo™ Mini PVDF Transfer Packs)
were obtained from Bio-Rad (Hercules, CA, USA). 4′,6-Diamidino-2-phenylindole (DAPI) was provided
by Vector Laboratories (Burlingame, CA, USA). Phosphate-buffered saline (PBS, ×20 concentration),
Phalloidin, Sulforhodamine 101 (Texas Red), and other reagents were purchased from VWR (Radnor, PA,
USA). Scrambled negative control siRNA (Catalogue no. AM4635), 5′-carboxyfluorescein (FAM)-labeled
negative control siRNA (Catalogue no. AM4620), and the siRNA targeting kinesin spindle protein
(KSP; Catalogue no. AM16704) were purchased from Ambion (Austin, TX, USA). The siRNAs targeting
Janus kinase 2 (JAK2) (Catalogue no. SI02659657; Sense: 5′-CCA UCA UAC GAG AUC UUA ATT-3′;
Antisense: 5′-UUA AGA UCU CGU AUG AUG GCT-3′), mLST8 (Catalogue no. SI00425474; Sense:
5′-GCU ACG ACG GCG UCA ACA ATT-3′; Antisense: 5′-UUG UUG ACG CCG UCG UAG CTG-3′,
and mammalian Target of Rapamycin (mTOR; Catalogue no. SI00070462; Sense: 5′-GGA GUG UUA
GAA UAU GCC ATT-3′; Antisense: 5′-UGG CAU AUU CUA ACA CUC CGG 3′) were purchased from
Qiagen (Valencia, CA). Primers for KSP (Forward: 5′-TCA CAA AAG CAA TGT GGA AAC CTA-3′;
Reverse: 5′-TCT GTC CAA AGA TTCA TTA ACT TGC A-3′), and JAK2 (Forward: 5′-AAC TGC
AGA TGC ACA TCA TTA CCT-3′; Reverse: 5′-TCG AAA TTG GGC CAT GAC A-3′) were designed
and ordered from Integrated DNA Technologies (IDT; Coralville, IA, USA). Monoclonal antibody
against JAK2 (Rabbit Mab 3230; catalog number: 3230) and anti-rabbit polyclonal secondary antibody
HRP-linked (7074V) were supplied by Cell Signaling Technology, Inc. (Danvers, MA, USA).
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2.2. Cell Lines
Three different breast cancer cell lines were included in this study to represent a variety of
phenotypes: MDA-MB-231 (triple-negative, but expected to express EGFR; ATCC® HTB-26™),
MDA-MB-468 (triple-negative, but over-expresses EGFR; ATCC® HTB-132™), and AU565
(over-expresses HER2, and expected to express EGFR; ATCC® CRL-2351™). All cell lines were
incubated for the duration of experiments in 37 ◦C and 5% CO2 level. Dulbecco’s modified Eagle’s
medium low glucose (DMEM), containing L-glutamine, sodium pyruvate, and glucose was used for
MDA-MB-231 and MDA-MB-468 cells. RPMI 1640 medium was used for AU565. All media were
supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin.
Cells were sub-cultured after reaching > 80% confluency and were discarded after ~40 passages.
2.3. Synthesis and Purification
Synthesis of [FR]4, [WR]5 [18], and [WK]5 [19] have been previously reported by us through
solid-phase synthesis. Synthesis of [R5K]W5 and [R6K]W6 was performed by using Fmoc-Arg(Pbf)-OH,
Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, and Fmoc-Lys(Dde)-OH as building block amino acids.
The appropriate resin, H-Arg (Pbf)-2-chlorotrityl resin (0.44 meq/g, 905 mg) was swelled in DMF
under dry nitrogen for 15 min, three times. The solvent was filtered off. The next Fmoc
protected amino acid (3 equiv.) was coupled to the N-terminal of the arginine in the presence
of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (3 equiv.),
and N,N-diisopropylethylamine (DIPEA) (6 equiv.) in DMF by agitating under dry nitrogen for
1.5 h. The reaction solution was filtered off after the completion of the coupling. The resin was washed
with N,N-dimethylformamide (DMF, 15 mL, 2 × 5 min.). Fmoc deprotection was performed by using
piperidine in DMF (20% v/v, 10 mL, 2 × 15 min.). The reaction solution was filtered off, and the resin
was washed with DMF (15 mL, 2 × 5 min.). The subsequent amino acids were coupled and deprotected
in a similar manner. Fmoc deprotection was performed on the last amino acid. Capping reaction by
acetic anhydride (3 equiv.) and (DIPEA) (6 equiv.) was performed on the last amino acid. The resin was
washed with DMF (15 mL, 2× 5 min.) and methanol (15 mL, 5 min.). The resin was dried under vacuum
for 4 h. The resin cleavage cocktail, dichloromethane:trifluoroethanol:acetic acid (DCM:TFE:AcOH;
35 mL:10 mL:5 mL) was freshly prepared. The cleavage cocktail was added to the resin, and the
solution was mixed for 3 h. The filtrate was evaporated under low pressure. Hexane (2 × 20 mL) and
DCM (2 × 15 mL) were added to the residue to remove the acetic acid from the mixture. The crude
material was solidified as a white solid. The crude peptide was dried under vacuum overnight.
After the formation, the structure of protected linear peptide was confirmed by MALDI mass
spectroscopy, the crude protected peptide was used for the cyclization reaction. The cyclization
occurred between the free COOH side in arginine and free NH2 side in lysine. Anhydrous
DMF (100 mL), anhydrous DCM (50 mL), N,N′-diisopropylcarbodiimide (DIC, 0.3 mmol, 188 µL),
and 1-hydroxy-7-azabenzotriazole (HOAt, 0.3 mmol, 122.5 mg) were added to the crude protected
linear peptide for cyclization. The solution was stirred under dry nitrogen overnight. After the
formation of the cyclic peptide was confirmed by MALDI analysis, the solvents were removed under
reduced pressure. The crude peptide was dried overnight. The cleavage cocktail (TFA, anisole,
thioanisole, 9:1:2 v/v/v and 50 mg of dithiothreitol (DTT), 20 mL total volume) was added to the crude
product. The mixture was stirred at room temperature for 5 h. The crude peptide was precipitated
in cold diethyl ether and centrifuged. Final compounds were purified by a reversed-phase HPLC
LC-20AP pump (Shimadzu Corp., Kyoto, Japan) using a gradient system of acetonitrile and water and
a reversed-phase preparative column (XBridge BEH130 Prep C18; 19 × 250 mm, 10 µm particle size,
Waters Corp., Milford, MA, USA). The structure of the compound was confirmed by high-resolution
MALDI-TOF mass spectroscopy (GT 0264; Bruker Inc., Billerica, MA, USA).
[R5K]W5: MALDI-TOF (m/z): C93H124N32O12, calculated: 1881.0076, found: 1883.8647 [M+2H]+;
[R6K]W6: MALDI-TOF (m/z): C110H146N38O14, calculated: 2223.1881, found: 2225.0676 [M+2H]+
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2.4. Complex Formation and Cytotoxicity of Peptide/siRNA Complexes
A Cell Counting 8 (CCK8) KIT (Biotool; Houston, TX, USA; also known as WST-8) was used
to evaluate the cytotoxicity of the peptides in breast cancer cell lines (MDA-MB-231, MDA-MB-468,
and AU565). Peptide/scrambled siRNA complexes were prepared by mixing siRNA and peptide in
normal saline, and formed spontaneously based on inter-ionic interaction. The mixture was incubated
for 30 min at room temperature to ensure complete complex formation. The ratio of peptide:siRNA was
calculated based on nitrogen/phosphate (N/P) ratio. The N/P ratios were calculated using Equation (1)
N/P =
# o f Moles o f peptide× # o f protonable nitrogens in each molecule o f peptide
# o f Moles o f siRNA× # o f phosphate groups in each siRNA molecule (1)
The peptide/siRNA complexes were formed with a wide range of N/P ratios (from 1 to 80) and
added to the cells in triplicate for a final siRNA concentration of 54 nM for all treatment groups.
Lipofectamine ® 2000 was used as control following manufacturer’s instructions to deliver a similar
siRNA final concentration. Cells were incubated at 37 ◦C, 5% CO2, for 24 h, after which 10 µL of CCK8
reagent was added to each well, and plates were incubated at 37 ◦C, 5% CO2, for 2 h. The absorbance
of each well was measured at 450 nm using the SpectraMAX M5 microplate reader. The results were
normalized to cells treated with normal saline (considered as 100%) after subtracting the signal from
blank wells (medium without cells in the plate with CCK-8 solution added).
2.5. Binding Affinity
Peptides were studied for their affinity for interionic interaction and binding to siRNA using a
SYBR green dye exclusion assay that we have previously reported [23,24]. Scrambled siRNA and
peptide solutions were mixed in normal saline with different N/P ratios (ranging between 0.05 to 40).
Free siRNA was used as a negative control. After 30 min incubation in room temperature 200 µL of
SYBR Green II dye (dilution of 1:10,000 was prepared using distilled water) was added to the samples,
and the fluorescence signal was measured in 96-well black plates (λ excitation: 485 nm, λ emission:
527 nm). The percentage of peptide-bound siRNA was calculated based on Equation (2) and plotted
against N/P ratio to calculate the ratio resulting in 50% binding (BR50) based on the linear portion of
the graph
% siRNA bound to peptide = 100− ( Fluorescence signal f or complex
Fluorescence signal f or f ree siRNA
× 100). (2)
2.6. Size and ξ-potential of Peptide/siRNA Complexes
In order to further characterize the peptide/siRNA particles, the hydrodynamic diameter and the
surface charge of the particles were determined using a Malvern Nano ZS Zetasizer (Westborough,
MA, USA) at 25 ◦C in disposable cuvettes and folded capillary cells, respectively. The ξ-potential of
the complexes was determined at 40 V, using Smoluchowski approximation.
2.7. Cellular Internalization (Flow Cytometry)
The capability of the peptides in internalizing siRNA into human cells was evaluated by monitoring
the uptake of fluorescence (FAM)-labeled scrambled siRNA and flow cytometry (BD-FACSVerse;
BD Biosciences; San Jose, CA, USA). All three breast cancer cell lines were used for these studies and
were seeded in 24-well plates (~200,000 cells per well). Peptide/siRNA complexes were prepared in N/P
ratios of 20:1, 40:1, and 80:1, with a final concentration of 36 nM for the fluorescent-labeled scrambled
siRNA. Cells exposed to siRNA complexes were incubated in 37 ◦C and standard growth conditions
for 24 h, after which cells were washed with clear HBSS (×2), trypsinized, and fixed using 3.7%
formaldehyde solution. Suspended cells were analyzed using FITC channel to quantify cell-associated
fluorescence. In order to evaluate the potential effect of the addition of DOPE to the carrier, DOPE was
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added to the complexes in a peptide/DOPE molar ratio of 3:2. After each flow cytometry analysis,
the percentage of cells with fluorescence signal and the mean fluorescence of the cell population was
calculated based on the calibration of the signal gated with non-treated cells (as the negative control),
so that the auto-fluorescence would be ~1% of the population.
2.8. Confocal Microscopy
Sterile cover slips were placed in the wells of 6-well plates and were treated with 2 µL of media
for 2 h. The cells were then seeded on the cover slips, and after 24 h growth period, were exposed to
FAM-labeled siRNA with a similar method as explained for flow cytometry experiments (N/P ratio of 20
was used for this set of experiments to avoid cytotoxicity). After 24 h, the growth media was removed,
and cells were washed with clear HBSS (×3). The cells were then fixed with 3.7% formaldehyde
solution in HBSS for 10 min, and were exposed to Texas Red (60 min in room temperature) and DAPI
(overnight, away from light and at room temperature) to stain cell membrane and nuclei, respectively.
Cover slips were examined using a Nikon A1R high definition resonant scanning confocal microscope
and a NIS-Elements software (AR 4.30.02, 64bit).
2.9. mRNA Interference (Real-Time Polymerase Chain Reaction; RT-PCR)
Cells were exposed to peptide/siRNA complexes formed with different N/P ratios (with final
siRNA concentration of 50 nM), and RNA was extracted from cells using TRIzol reagent 48 h after
exposure, following the manufacturer’s instructions. One mL of TRIzol reagent was added for each
1 × 106 cells, and the cell lysates were incubated at room temperature for 5 min The lysate was then
treated with chloroform at v/v chloroform:TRIzol ratio of 1:5. The contents of the tubes were mixed
and incubated for 2–3 min at room temperature, and the aqueous phase was collected. The total
RNA was precipitated using isopropanol and was pelleted by centrifugation (12,000 g for 10 min in
4 ◦C). The pellet was washed with 75% ethanol, and the extracted RNA was dissolved in RNase-free
water. The total extracted RNA in each sample was quantified by BioSpec-Nano (Shimadzu, Columbia,
MD, USA). The cDNA was synthesized by reverse transcription of 0.5–1 µg RNA using iScriptTM
reverse transcription Supermix and the C1000 Touch® thermocycler (Bio-Rad, Hercules, CA, USA),
following the manufacturer’s guidelines. A CFX96TM optical module (Bio-Rad) was used for RT-PCR
analysis, and human β-actin was used as the endogenous gene to normalize the mRNA level of
targeted proteins. RT-PCR was performed using iTaq universal SYBR green Supermix kit. The RT-PCR
ran for 40 cycles (95 ◦C for 2 min., followed by 40 cycles of denaturation 95 ◦C for 5 s and annealing
temperature 55 ◦C for 30 s, and a final extension step at 65 ◦C for 5 s). The analysis was performed by
calculating ∆CT (the difference in CTs for the target mRNA and the endogenous control), ∆∆CT (based
on ∆CTs observed for ‘no treatment’ and the treatment groups) and relative quantity (RQ).
2.10. Protein Quantification (Western Blot)
The expression of the targeted protein was analyzed by western blot. Cell lysates were prepared
according to the standard protocol using RIPA buffer. Briefly, cells exposed to siRNA complexes were
collected by trypsinization after 48 h of exposure and were centrifuged at 600–800 RPM for 5 min.
The supernatant was discarded, and the cell pellet was washed three times with ice cold PBS. The pellet
was resuspended in RIPA buffer (100 µL of buffer for 25 µL of cell pellet), and the cell lysates were then
incubated on ice for one hour, during which the tubes were sonicated for 3 min every 10 min The tubes
were then centrifuged for 15 min at 12,000× g (at 4 ◦C). Microtubes were pre-cooled to transfer the
supernatant, and total protein concentration was determined using BSA assay. Briefly, 200 µL of work
reagent (50:1 A:B) was added to 25 µL of standard and unknown samples in triplicate into a 96-well
plate, and the plate was mixed on a plate shaker for 30 s. The plate was then incubated at 37 ◦C and 5%
CO2 for 30 min. The absorbance was measured at 562 nm using SpectraMAX M5 microplate reader.
Protein (25 µg) was loaded per well in a 10% Mini-PROTEAN® TGX Stain-Free™ Protein gel using
electrophoresis buffer (0.192 M glycine, 25 mM Tris, 0.1% SDS), and the electrophoresis was run for
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30 min with 200 V. The gel was then transferred onto a Trans-Blot® Turbo™ Mini PVDF membrane
(Catalog no. 1704156). Membranes were blocked in BSA 5% for 3 h, and then incubated overnight
(at 4 ◦C) with the primary anti-body (1:1000 in TBS-T). The membrane was then washed with TBS-T six
times (5 min each time), and was subsequently incubated with the secondary HRP-linked antibody
(1:1000 in TBS-T) for 1 h, followed by the washing steps. Detection was done by ECL Detect Kit using
ChemiDoc imager (Bio-Rad).
3. Results and Discussion
3.1. Chemistry
As a representative example, the synthesis of [R5K]W5 is shown in Scheme 1. Synthesis of
[R5K]W5 was performed by using Fmoc solid-phase peptide synthesis. The appropriate resin,
H-Arg(Pbf)-2-chlorotrityl resin was used as the solid support. Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH,
and Dde-Lys(Boc)-OH were used as building block amino acids in the assembly of the peptide on
the resin. After the protected linear peptide formation was confirmed by MALDI mass spectroscopy
(see Supporting Information), the crude peptide was used for the cyclization reaction in the presence
of anhydrous DMF, anhydrous DIC, and HOAt. The crude peptide was precipitated in cold diethyl
ether and was purified by HPLC.
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containing positively-charged arginine residues attached to hydrophobic tryptophan chain, [R5K]W5
and [R6K]W6 (Figure 2). The goal was to determine whether changing the orientation of arginine and
tryptophan residues and the addition of a linear hydrophobic chain can affect the siRNA delivery.
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3.2. Cellular Internalization
The study of siRNA intracellular delivery using cyclic and hybrid (positively charged ring and
hydrophobic chain) peptides was performed using flow cytometry in two triple-negative breast cancer
cell lines (MDA-MB-231 and MDA-MB-468) for cyclic peptides and an additional breast cancer cell line
(AU565, which over-expresses HER2, and is expected to express EGFR as well) for hybrid peptides.
We investigated the efficiency of three N/P ratios for each peptide, and also determined the effect of an
additional hydrophobic moiety to the carrier by adding DOPE to the formulation of each peptide/siRNA
complex (Figure 3). Among cyclic peptides, [FR]4 and [WK]5 showed no significant difference with
cells exposed to normal saline at any studied N/P ratio. However, [WR]5 indicated significant efficacy
in cellular internalization of siRNA. In MDA-MB-231 cells, both mean fluorescence of the whole cell
population and the percentage of the cells with fluorescent signal were improved by increasing the N/P
ratio. Also, the addition of DOPE significantly increased internalization of the siRNA in all three N/P
ratios (Figure 3A,B). The average mean fluorescence for N/P ratio of 40 after addition of DOPE was
slightly higher than N/P ratio of 80; however, the difference was not statistically significant. Generally,
a similar uptake efficiency was observed for [WR]5 in MDA-MB-468 cells (maximum mean fluorescence
of 459 was achieved with [WR]5/DOPE at N/P ratio of 20, compared to maximum mean fluorescence
of 454 for [WR]5/DOPE at N/P ratio of 40 in MDA-MB-231 cells). However, while similar improved
internalization was observed with the addition of DOPE to the delivery system, the trend among
the different N/P ratios was different. Without DOPE, an N/P ratio of 40 showed the highest mean
fluorescence, where after the addition of DOPE, an N/P ratio of 20 showed the highest efficiency in
terms of mean fluorescence. There was no significant difference in the percentage of cells positive
for fluorescence signal in MDA-MB-468 cells among [WR]5 study groups, which was partially due to
overall high percentages (69–77%) observed for all groups.
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Similar N/P ratios were used for hybrid peptides, and the effect of the addition of DOPE to the
delivery system was also investigated. Both peptides demonstrated significant efficiency in delivering
siRNA to different breast cancer cell lines, and similar to our observation for [WR]5, the addition of
DOPE increased the mean fluorescence for both peptides (although not always statistically significant
in MDA-MB-468 cells; Figure 3). However, the efficacy of siRNA uptake with the peptides in this class
seemed to depend on the cell line: while both peptides created similar mean fluorescence readings to
Polymers 2019, 11, 703 11 of 20
in MDA-MB-231 cells, addition of DOPE had a more significant effect on improving the internalization
level with [R6K]W6 compared to [R5K]W5 at N/P ratios of 40 and 80 (mean fluorescence of 1359
compared to 671 for N/P ratio of 40, respectively; Figure 3A). On the other hand and in AUC65 cells,
[R5K]W5 created higher mean fluorescence, both with and without DOPE (mean fluorescence readings
of 1942, 921, and 1392 for N/P ratios of 20, 40, and 80 with DOPE, respectively, compared to 472, 611,
and 1237 for corresponding N/P ratios for [R6K]W6; Figure 3E). However, there was no significant
difference between the overall mean fluorescence values observed for the two peptides in MDA-MB-468
cells (Figure 3C). Interestingly, the effect of N/P ratio on the siRNA internalization levels was also
cell type dependent: while the highest mean fluorescence was observed with highest N/P ratio in
MDA-MB-468 cells (for both peptides, with and without DOPE), a similar trend was not observed in
the other two cell lines. In MDA-MB-231 cells, N/P ratio of 40 provided the highest N/P ratio for both
peptides (not significantly different with N/P ratio of 20 in [R5K]W5 with DOPE). On the other hand,
more variability was observed in AU565 cells, where the highest mean fluorescence was observed for
N/P ratios of 80 and 20 for [R5K]W5 with and without DOPE, respectively, and N/P ratio of 80 for
[R6K]W6 both with and without DOPE. Statistically significant differences were less frequent in terms
of percentage of the cells positive for fluorescence signal, mostly due to high percentages observed
for most study groups (Figure 3B,D,F). However, a trend similar to the mean fluorescence values was
observed in the percentage of fluorescence-positive AU565 cells (Figure 3F).
Overall, the performance of the peptide careers was not consistent in different cell lines. This is
expected and has been reported previously by many researchers [4,25,26]. In fact, many cell lines
are notorious as being “hard-to-transfect”. This is perhaps due to multiple factors, including the
receptor composition on the cell membrane and growth media, among others. However, a similar
trend was observed for the efficiency of each designed peptide in a different cell line, which indicates
the overall efficiency of the selected approach. Among cyclic peptides, [FR]4 and [WK]5 showed no
efficiency in internalizing siRNA into triple-negative breast cancer cell lines (Figure 3). This was not
surprising since we observed a similar trend when [FR]4 was evaluated along with [WR]5 for delivery
of fluorescent-labeled lamivudine. [FR]4 showed significantly less molecular transporter property
when compared with [WR]5 [18]. Furthermore, when [FR]4, [WK]5, and [WR]5 were compared for
self-assembly properties, only [WR]5 generated self-assembled nanostructures. These data indicate
that an optimal balance of positive charge and hydrophobicity is required to generate self-assembled
structures and molecular transporter property. The presence of indole ring of tryptophan is presumed
to be critical for the generation of more efficient hydrophobic interactions with the cell membrane and
self-assembly. It seems that combination of arginine and tryptophan offers characteristics that are not
provided when arginine is combined with phenylalanine or in combination of lysine and tryptophan.
Overall, hybrid peptides showed a higher efficiency compared to cyclic peptides, which could be
explained by their specific design. The hydrophobic portion of the peptide is completely separated in
[R5K]W5 and [R6K]W6, which minimizes the risk of a steric hindrance with the interionic interaction
with siRNA. [R6K]W6 showed the highest mean fluorescence in MDA-MB-231 cells, which is expected
due to a higher number of primary amines (six groups compared to five for [WR]5 and [R5K]W5).
This significant difference was not observed for the percentage of siRNA-positive cells (Figure 3B).
While mean fluorescence represents the total siRNA signal associated with the cell population,
each cell can be recognized as siRNA-positive with internalizing a few copies of siRNA. Therefore,
mean fluorescence can vary almost without limit, where the percentage is a limited scale. We frequently
observe near maximum percentages for different study groups with effective delivery systems,
in which case the mean fluorescence can be used to differentiate the efficiency of different carriers
used. The maximum siRNA internalization in AU565 cells was observed with [R5K]W5, which was
unexpected. However, the need for optimization of the delivery system based on the targeted cell line
has been emphasized by many experts, and different performance of carriers in different cell lines is
somewhat expected.
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The second variable in uptake studies was the N/P ratio. The overall positive charge in the
peptide/siRNA complexes is contributed by the primary amine groups (which were considered
‘protonable’ in the N/P calculation method). A higher N/P ratio is usually expected to create a higher
interaction with the negatively-charged cell membrane. In fact, a positive overall charge (> + 5 mV) is
usually recommended for effective delivery of nucleotides [24,27,28]. It is, however, hypothesized that
increased N/P ratio and resultant enhanced interaction with cell membrane also leads to increased
cytotoxicity [29]. This correlation between internalization efficiency and the level of cytotoxicity is
well-established in polyethyleneimine (PEI) positively-charged polymers [4,24,30]. This expected trend
was observed in our siRNA internalization studies using flow cytometry for most of the study group.
Increasing N/P ratio from 20 to 40 increased mean fluorescence in all study groups (in some cases the
increase was not statistically significant) with one exception: [R5K]W5 in AU565 cells, where N/P ratio
of 20 resulted in the highest mean fluorescence. The increase in N/P ratio from 40 to 80, however, did not
always increase the level of internalization indicated by mean fluorescence, which could indicate a
‘saturation’ in the uptake of complexes at the N/P ratio of 40. The percentage of the cells positive for
the fluorescent signal did not show the similar trend in all cases, which again could be due to the high
level of internalization observed for N/P ratio of 20, which limited the room for improvement of the
number of “transfected” cells.
The secondary structures of the peptides along with the chemical structures could contribute
significantly to their bioactivity. The CD spectra of α-helices have two negative peaks of similar
magnitude at 222 nm and 208 nm, and a larger positive peak at 195 nm. A ratio of 222 nm/208 nm of
about 0.8 suggests a single stranded α-helix while a ratio of about 1 suggests a two-stranded coil–coil of
α-helix. We have already conducted and reported CD studies for peptides containing tryptophan and
arginine residues [WR] (n = 3–5) [19] and peptides containing tryptophan and lysine residue [WK]5 [31].
The secondary structures of these cyclic peptides were distinct from known α and β structures as
previously reported by us [19,20]. CD spectra of the aqueous solution of [WR]n (n = 3–5, 100 µM)
showed two negative bands at approximately 202–205 nm and 214–216 nm and a positive band around
229 nm, suggesting a distorted helical structure [19]. The CD spectra of [WR]5 exhibited a distinct
minimum of ellipticity around 202–205 nm, suggesting that the peptides exist mostly in random coil
states. Furthermore, the peptide showed strong negative bands around 214–216 nm and a positive band
at around 190, which are characteristic of the formation of distorted β-sheet structures [19]. CD spectra
of [WK]5 has also been previously reported in the same publication. CD revealed a negative band at
approximately 216 nm and a positive band around 230 nm. The negative 205 peak is less obvious than
[WR]5. These CD spectra are distinct from a helical structure. In general, [WR]5 shows a distorted
helical structure that may explain more efficient cellular permeability. This distorted helical structure
is less obvious in [WK]5. However, neither of the two peptides demonstrated fully helical structure.
We have conducted preliminary CD studies on several new hybrid peptides along with [R5K]W5 and
[R6K]W6. For example, CD study on [R5K]W7 showed a negative peak at about between 222 to 227 nm
that is significantly different than [WR]5. The peak at 222 nm is consistent with an α-helical protein,
but no peak at 208 nm was observed to confirm the helical structure. It also showed positive band
near 287 and 295 nm in near UV, suggesting the stacking or self-assembly of tryptophan residues.
We also studied the effect of increasing the overall hydrophobicity of the delivery system by adding
DOPE to the formulation. We have previously reported the enhanced cellular internalization of siRNA
with increased hydrophobicity through conjugation of fatty acids to PEI 2.0 kilodaltons [24] and small
positively-charged peptides [23]. It is hypothesized that increased hydrophobicity of the siRNA/carrier
complex would enhance interaction with the cell membrane, which in turn is expected to improve
cellular uptake of siRNA. This approach has also been reported by other researchers via conjugation
of hydrophobic moieties to the carrier or the siRNA itself [32–34]. We have previously reported the
simple addition of DOPE to the siRNA/peptide mixture as an efficient approach in enhancing siRNA
internalization by human breast cancer cells [23]. In this study, the addition of DOPE created a similar
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enhancing effect on siRNA internalization in all study groups in a different selected cell line, which of
course was not always statistically significant.
The cell internalization of the fluorescent-labeled siRNA was also visualized using confocal
microscopy (Figure 4). The margins of cytoplasm are visualized with color red (due to Texas
Red staining of cell membrane), and the nuclei are visualized with a blue color (due to DAPI
staining). While DOPE alone did not internalize FAM-labeled siRNA, all three studied peptides
created significant internalization when combined with DOPE. In addition to visual detection of
siRNA in breast cancer cells, this set of experiments confirmed that DOPE alone does not create a
significant siRNA internalization, which was observed in the flow cytometry experiments, and has
been previously reported for a different peptide design by our research group [23].
Figure 4. Confocal images of MDA-MB-231 (A) and MDA-MB-468 (B) cells exposed to FAM-labeled
siRNA. The red, blue and green channels visualize Texas Red (used to stain the cell membrane),
DAPI (stained the nuclei), and FAM-labeled siRNA.
3.3. Binding Affinity
The affinity to bind to siRNA was determined for [WR]5, [R5K]W5, and [R6K]W6 in a wide range
of N/P ratios (Figure 5A). Complete binding was achieved with N/P ratio of 40 for all three peptides.
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However, the binding affinity was the strongest for [WR]5 (BR50 = 4.0). This could be explained by
steric hindrance caused by the hydrophobic side chain on [R5K]W5 and [R6K]W6 peptides. [R6K]W6
showed a higher affinity than [R5K]W5 (BR50 of 6.9 compared to 8.3, respectively), which was also
expected due to presence of six positively charged nitrogens in the structure of [R6K]W6 (compared to
five positive charges for [R5K]W5).
3.4. Particle Size and Surface Charge
The hydrodynamic diameter and the ξ-potential of the peptide/siRNA particles were studied at
N/P ratio of 20 to further characterize the peptide-siRNA interaction (Figure 5B). While the size of
particles was similar for [WR]5 and [R6K]W6 (~200 nm), particles formed with [R5K]W5 had a larger
diameter (~310 nm). However, while all particles had a positive surface charge, the ξ-potential of
particles formed with [R6K]W6 was significantly higher than the other peptides. This is probably due
to the extra positive charge on the structure of this peptide.
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II exclusion assay (n = 3). Among the selected peptides, [WR]5 showed the hig est binding affinity
to siRNA; (B) Particle size, and surface ch rge of th particles w re determined at an N/P ratio of
20 (Zeta Sizer; n = 3). [R5K]W5 and [R6K]W6 showed t e highest particle size and surface charge,
respectively, among the peptides included in this study.
3.5. Cytotoxicity
Safety of a deliver s st is a key ch racteristic for the linical applications of th carrier.
We investigated the tox city of the designed peptides after complex formation with siRNA, at different
N/P ratios rangin 1 to 80, in all bre st cancer cell lines included in the study (Figure 6).
In DA-MB-231 cells, [R5K]W5 showed no signifi ant eff ct on the viability of the c lls in the N/P
range studied. However, both [WR]5 and [R6K]W6 showed signs of toxicity in N/P ratios of 40 (except
[WR]5 without DOPE) and 80. The drop in viability was most significant for cells exposed to scrambled
siRNA/DOPE/peptide complexes at N/P ratio of 80 (13% compared to NT group; Figure 6A). A similar
pattern was observed in MDA-MB-468 and AU565 cells, where [R5K]W5 was the least toxic of the
three peptides (the significant difference was observed only for N/P ratio of 80, and the lowest viability
observed was 72.6% for [R5K]W5 without DOPE in AU565 cells). The level of toxicity of [WR]5 was
most significant in MDA-MB-468 cells, where N/P ratio of 80 caused 18.2 and 6.6% viability with and
without DOPE (Figure 6B). In AU565 cells, similar to MDA-MB-231, the highest drop in viability was
observed for [R6K]W6 with N/P ratio of 80 (Figure 6C). Overall, the addition of DOPE did not seem to
change the cytotoxicity pattern significantly for any of the peptides. Also, exposing cells to different
concentrations of DOPE alone (corresponding to the final concentrations incorporated into carriers
at the different N/P ratios) did not reduce cell viability in any of the selected cell lines. However,
the level of effect on the viability was slightly more in MDA-MB-468 and AU565 cells for the highest
concentration used. Lipofectamine ® 2000 reduced the cell viability percentage in all three cell lines
significantly (~75–80% compared to NT group).
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To evaluate the cytotoxicity of [WR]5, [R5K]W5, and [R6K]W6 alone (without siRNA complexation)
in healthy cells, cell viability assay was conducted in LLCPK (normal kidney cells) at the experimental
concentration of 25µM. None of the compounds showed any significant cytotoxicity at this concentration
in the selected cell line (data not shown).
As emphasized before, a correlation between the efficacy of cellular internalization and cytotoxicity
is usually expected for positively charged siRNA carriers. An increased cytotoxicity was in fact detected
with increasing N/P ratio for all selected peptides in all three cell lines, and was most significant with
N/P ratio of 80. [R6K]W6 showed the highest level of toxicity in all cell lines, which is consistent with
the expectation due to the presence of six primary amine groups compared to five groups for the
other two peptides. [R5K]W5 showed the least level of toxicity in all three cell lines, and in fact the
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cell viability was not significantly different at N/P ratio of 80 compared to the ‘No Treatment’ group
in MDA-MB-231 cells. This indicates that [R5K]W5 is a more promising carrier compared to [WR]5
in both efficiency and safety aspects. No significant toxicity was detected at N/P ratio of 20 for any
of the peptides, and therefore this ratio was selected for protein silencing experiments to avoid the
interference of toxicity with the silencing effect (despite higher internalization observed for N/P ratios
of 40 and 80 in most of the study groups).
3.6. Protein Silencing
We targeted two model proteins as a proof of concept using the designed peptides that showed
significant uptake in human breast cancer cells. The effect of targeting KSP was analyzed at mRNA
level by real-time PCR and on cell viability using CCK assay (Figure 7). Peptide/siRNA complexes were
formed at N/P ratio of 20 to avoid the toxic effect on the MDA-MB-231 cells. Also, scrambled siRNA
(control siRNA, or ‘CsiRNA’) was only delivered with DOPE included in the delivery system as a
negative control. Delivering siRNA targeting KSP decreased the mRNA level of the targeted protein
compared to the negative control group (statistically significant; p < 0.05). Similar to the trend observed
in the cellular internalization study, the addition of DOPE increased the silencing efficiency for all
selected peptides. The level of silencing was most significant in [R5K]W5/DOPE delivery system
(relative quantity of 0.32; Figure 7A). The level of silencing efficiency with addition of DOPE to
both [R5K]W5 and [R6K]W6 was significantly higher than Lipofectamine (used as positive control).
A CCK assay was also used to investigate the viability of the MDA-MB-231 cells after targeting KSP.
A very similar trend was observed in the viability pattern of the study groups with minor differences:
scrambled siRNA delivered with [WR]5 demonstrated a slight decrease in viability of the exposed cells
(85% normalized to cells treated with normal saline) that was statistically significant. Also, unlike the
real-time PCR results, where [R6K]W6/DOPE showed more significant efficacy in downregulating KSP
mRNA compared to [WR]5/DOPE study group, no significant difference was observed in the effect of
the two delivery systems on the viability of the cells targeted with KSP siRNA. Again, targeting KSP
by [R5K]W5/DOPE showed the most significant effect on cell viability (20.2%; Figure 7B); however,
the diminished viability was more significant than Lipofectamine with both [R5K]W5 and [R6K]W6
after addition of DOPE to the delivery system.
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Figure 7. Silencing kinesin spindle protein (KSP) in MDA-MB-231 cells: (A) Silencing was evaluated
at mRNA level using real-time PCR. Control siRNA (CsiR A, only delivered ith DOPE) or siR
targeting selected protein (delivered with or without DOPE) were delivered using the designed peptides
at N/P ratio of 20. All relative quantities were normalized based on mRNA levels of cells treated with
normal saline (not shown). All relative quantities for targeted siRNAs were significantly different
with CsiRNA group, and all mRNA levels for targeted siRNA groups were significantly different with
CsiRNA group, and all mRNA levels for targeted siRNA groups were significantly different from
corresponding ‘without DOPE’ levels (p < 0.05). (B) Effect of silencing on MDA-MB-231 cell viability
was evaluated using CCK assay. Similar study groups were used, and results were normalized based
on viability of the cells treated with normal saline (not shown). A similar trend in statistical analysis
was observed.
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KSP has been identified as a viable target for siRNA silencing as a therapeutic approach in cancer
therapy. Delivering siRNA via a variety of delivery systems targeting KSP in different cancer types
has shown effective apoptosis induction and tumor growth retardation in vitro and in vivo [35–40].
In fact, clinical trials have indicated the efficiency of simultaneous silencing of KSP and vascular
endothelial growth factor (VEGF) in colorectal [41] and endometrial cancer patients [42] with liver
involvement. We selected KSP as a model protein to investigate silencing efficiency of the designed
selected peptides in MDA-MB-231 cells, and to determine the effect of this silencing on the cell viability
as the phenotypical end result of the siRNA delivery. While delivering KSP siRNA without DOPE
had a modest effect on mRNA levels as well as the cell viability for all three peptides, the addition of
DOPE enhanced the effect significantly in all study groups, which was most significant for [R5K]W5
(Figure 7). This is further confirmation of the efficient siRNA delivery via the designed peptides and
timely release of siRNA from the complexes in the cytoplasm. Although [R6K]W6 showed the highest
level of siRNA cellular internalization among the designed peptides in this cell line with N/P ratios of
40 and 80, the lower silencing efficiency of this peptide is not surprising due to the lower N/P ratio
selected to avoid non-specific toxicity.
A similar study design was used to investigate targeting JAK2 protein in the same cell line, and in
addition to the real-time PCR, western blot was performed to confirm the effect of siRNA delivery
on the protein expression level (Figure 8). The analysis of mRNA levels of JAK2 in different study
groups revealed a similar pattern to our observation for KSP. Again, delivering siRNA without DOPE
decreased the mRNA level compared to scrambled siRNA for all selected peptides, and adding DOPE
to the delivery system further enhanced this effect significantly, which was again a silencing efficiency
that was significantly higher than Lipofectamine, for both [R5K]W5 and [R6K]W6. [R5K]W5/DOPE
again showed the most significant drop in mRNA level (~80% silencing; Figure 8A). This delivery
system was selected for western blotting to confirm our observations at the protein level (Figure 8B).
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In order to further confirm the silencing efficiency of peptide/DOPE/siRNA complexes, JAK2 was
selected as a second model protein. JAK/STAT pathway is a crucial signaling cascade known to be
involved in the proliferation and survival of different cancer cells [43]. Silencing J K2 has reported
to enhance apoptosis in hu an gastric cancer cells [44], and delivering J 2 si has sensitized
resistant ovarian cancer cells to paclitaxel [45]. Level of mRNA downregulation showed a similar trend
to our observations with KSP silencing with the most efficient drop in mRNA levels for [R5K]W5/DOPE
delivery system. In order to confirm the silencing efficiency at the protein level, we performed western
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blotting to determine inhibition of JAK2 expression by this delivery system, which further confirmed
the silencing efficiency of the selected carriers, in correlation with our observations in uptake and
PCR studies.
4. Conclusions
It was expected that incorporation of positively-charged and hydrophobic residues in the structure
could greatly improve the interaction with the negatively charged phosphate and hydrophobic
chains in the cellular phospholipid bilayer, respectively, and enhance the cellular delivery of siRNA.
This expectation was based on the previous data showing that cyclic peptides containing alternate
tryptophan and arginine residues [WR]5 and [WR]4 and the corresponding peptide-capped gold
nanoparticles improved the cellar delivery of siRNA [22]. Consistent with the previous results,
we found that [WR]5 was an efficient transporter of siRNA. We also found that cellular delivery of
siRNA was significantly improved in the presence of peptides containing arginine and tryptophan
residues with a cyclic peptide containing all the positively-charged residues attached to tryptophan
chain, suggesting more efficient interactions of the trypotphan chain with the hydrophobic residues
and positively-charged residues of the peptide with the negatively-charged phosphate group in the
phospholipid bilayer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4360/11/4/703/s1.
Author Contributions: Conceptualization, K.P. and H.M.A.; Methodology, K.P and H.M.A.; Validation, K.P.
and H.M.A.; Formal Analysis, H.M.A.; Investigation, S.M. (peptide synthesis), E.B. (silencing), F.A. (confocal
microscopy), R.L. (flow cytometry), M.C. (uptake and cytotoxicity), A.A. (binding affinity), and R.H. (size and
zeta potential); Resources, P.M.; Writing—Original Draft Preparation, S.M.; Writing—Review & Editing, K.P and
H.M.A.; Supervision, K.P and H.M.A.
Funding: This research received no external funding.
Acknowledgments: We acknowledge funding support from Chapman University School of Pharmacy.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ghildiyal, M.; Zamore, P.D. Small silencing RNAs: An expanding universe. Nat. Rev. Genet. 2009, 10, 94–108.
[CrossRef] [PubMed]
2. Ender, C.; Meister, G. Argonaute proteins at a glance. J. Cell Sci. 2010, 123, 1819–1823. [CrossRef] [PubMed]
3. Kim, V.N.; Han, J.; Siomi, M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10,
126–139. [CrossRef] [PubMed]
4. Aliabadi, H.M.; Landry, B.; Sun, C.; Tang, T.; Uludag, H. Supramolecular assemblies in functional siRNA
delivery: Where do we stand? Biomaterials 2012, 33, 2546–2569. [CrossRef]
5. De Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease: A progress
report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6, 443–453. [CrossRef]
6. Chabot, S.; Teissie, J.; Golzio, M. Targeted electro-delivery of oligonucleotides for RNA interference:
SiRNA and antimir. Adv. Drug Deliv. Rev. 2015, 81, 161–168. [CrossRef] [PubMed]
7. Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for
gene-based therapy. Nat. Rev. Genet. 2014, 15, 541–555. [CrossRef]
8. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.;
Radka, S.; Jadhav, V.; et al. Potent and persistent in vivo anti-hbv activity of chemically modified siRNAs.
Nat. Biotechnol. 2005, 23, 1002–1007. [CrossRef]
9. Titze-de-Almeida, R.; David, C.; Titze-de-Almeida, S.S. The race of 10 synthetic RNAi-based drugs to the
pharmaceutical market. Pharm. Res. 2017, 34, 1339–1363. [CrossRef]
10. Huang, Y. Preclinical and clinical advances of galnac-decorated nucleic acid therapeutics. Mol. Ther. Nucleic
Acids 2017, 6, 116–132. [CrossRef] [PubMed]
11. Chaudhary, A.; Garg, S. SiRNA delivery using polyelectrolyte-gold nanoassemblies in neuronal cells for
bace1 gene silencing. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 80, 18–28. [CrossRef] [PubMed]
Polymers 2019, 11, 703 19 of 20
12. Chen, J.; Sun, X.; Shao, R.; Xu, Y.; Gao, J.; Liang, W. Vegf siRNA delivered by polycation liposome-encapsulated
calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int. J. Nanomed. 2017,
12, 6075–6088. [CrossRef] [PubMed]
13. Zheng, G.; Shen, Y.; Zhao, R.; Chen, F.; Zhang, Y.; Xu, A.; Shao, J. Dual-targeting multifuntional mesoporous
silica nanocarrier for codelivery of siRNA and ursolic acid to folate receptor overexpressing cancer cells.
J. Agric. Food Chem. 2017, 65, 6904–6911. [CrossRef] [PubMed]
14. Ohyama, A.; Higashi, T.; Motoyama, K.; Arima, H. In vitro and in vivo tumor-targeting siRNA delivery
using folate-peg-appended dendrimer (g4)/alpha-cyclodextrin conjugates. Bioconjug Chem 2016, 27, 521–532.
[CrossRef] [PubMed]
15. Ohyama, A.; Higashi, T.; Motoyama, K.; Arima, H. Ternary complexes of folate-peg-appended dendrimer
(g4)/alpha-cyclodextrin conjugate, siRNA and low-molecular-weight polysaccharide sacran as a novel
tumor-selective siRNA delivery system. Int. J. Biol. Macromol. 2017, 99, 21–28. [CrossRef]
16. Chugh, A.; Eudes, F.; Shim, Y.S. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living
cells. IUBMB Life 2010, 62, 183–193. [CrossRef] [PubMed]
17. Torchilin, V.P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and
gene delivery. Biopolymers 2008, 90, 604–610. [CrossRef] [PubMed]
18. Mandal, D.; Nasrolahi Shirazi, A.; Parang, K. Cell-penetrating homochiral cyclic peptides as nuclear-targeting
molecular transporters. Angew. Chem. Int. Ed. Engl. 2011, 50, 9633–9637. [CrossRef] [PubMed]
19. Mandal, D.; Tiwari, R.K.; Shirazi, A.N.; Oh, D.; Ye, G.; Banerjee, A.; Yadav, A.; Parang, K. Self-assembled
surfactant cyclic peptide nanostructures as stabilizing agents. Soft Matter 2013, 9. [CrossRef]
20. Nasrolahi Shirazi, A.; Tiwari, R.K.; Oh, D.; Banerjee, A.; Yadav, A.; Parang, K. Efficient delivery of
cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.
Mol. Pharm. 2013, 10, 2008–2020. [CrossRef]
21. Oh, D.; Darwish, S.A.; Shirazi, A.N.; Tiwari, R.K.; Parang, K. Amphiphilic bicyclic peptides as cellular
delivery agents. ChemMedChem 2014, 9, 2449–2453. [CrossRef] [PubMed]
22. Shirazi, A.N.; Paquin, K.L.; Howlett, N.G.; Mandal, D.; Parang, K. Cyclic peptide-capped gold nanoparticles
for enhanced siRNA delivery. Molecules 2014, 19, 13319–13331. [CrossRef]
23. Do, H.; Sharma, M.; El-Sayed, N.S.; Mahdipoor, P.; Bousoik, E.; Parang, K.; Montazeri Aliabadi, H.
Difatty acyl-conjugated linear and cyclic peptides for siRNA delivery. ACS Omega 2017, 2, 6939–6957.
[CrossRef] [PubMed]
24. Aliabadi, H.M.; Landry, B.; Bahadur, R.K.; Neamnark, A.; Suwantong, O.; Uludag, H. Impact of lipid
substitution on assembly and delivery of siRNA by cationic polymers. Macromol. Biosci. 2011, 11, 662–672.
[CrossRef]
25. Capel, V.; Vllasaliu, D.; Watts, P.; Stolnik, S. Insight into the relationship between the cell culture model,
cell trafficking and siRNA silencing efficiency. Biochem. Biophys. Res. Commun. 2016, 477, 260–265. [CrossRef]
26. Nakamura, T.; Kuroi, M.; Fujiwara, Y.; Warashina, S.; Sato, Y.; Harashima, H. Small-sized, stable lipid
nanoparticle for the efficient delivery of siRNA to human immune cell lines. Sci. Rep. 2016, 6, 37849.
[CrossRef] [PubMed]
27. Cao, N.; Cheng, D.; Zou, S.; Ai, H.; Gao, J.; Shuai, X. The synergistic effect of hierarchical assemblies of
siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32, 2222–2232.
[CrossRef] [PubMed]
28. Convertine, A.J.; Benoit, D.S.; Duvall, C.L.; Hoffman, A.S.; Stayton, P.S. Development of a novel endosomolytic
diblock copolymer for siRNA delivery. J. Control. Release 2009, 133, 221–229. [CrossRef] [PubMed]
29. Zhang, J.; Fan, H.; Levorse, D.A.; Crocker, L.S. Ionization behavior of amino lipids for siRNA delivery:
Determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane
interactions. Langmuir 2011, 27, 1907–1914. [CrossRef]
30. Godbey, W.T.; Wu, K.K.; Mikos, A.G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes
for gene delivery. Proc. Natl. Acad. Sci. USA 1999, 96, 5177–5181. [CrossRef]
31. Nasrolahi Shirazi, A.; Tiwari, R.K.; Oh, D.; Sullivan, B.; McCaffrey, K.; Mandal, D.; Parang, K. Surface decorated
gold nanoparticles by linear and cyclic peptides as molecular transporters. Mol. Pharm. 2013, 10, 3137–3151.
[CrossRef]
32. Hoyer, J.; Neundorf, I. Knockdown of a g protein-coupled receptor through efficient peptide-mediated
siRNA delivery. J. Control. Release 2012, 161, 826–834. [CrossRef]
Polymers 2019, 11, 703 20 of 20
33. Kim, W.J.; Chang, C.W.; Lee, M.; Kim, S.W. Efficient siRNA delivery using water soluble lipopolymer for
anti-angiogenic gene therapy. J. Control. Release 2007, 118, 357–363. [CrossRef] [PubMed]
34. Sarett, S.M.; Kilchrist, K.V.; Miteva, M.; Duvall, C.L. Conjugation of palmitic acid improves potency and
longevity of siRNA delivered via endosomolytic polymer nanoparticles. J. Biomed. Mater. Res. A 2015, 103,
3107–3116. [CrossRef]
35. Lee, J.; Ahn, H.J. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA
delivery carrier for ovarian cancer therapy. Biochem. Biophys. Res. Commun. 2018, 503, 1716–1722. [CrossRef]
[PubMed]
36. Klein, P.M.; Kern, S.; Lee, D.J.; Schmaus, J.; Hohn, M.; Gorges, J.; Kazmaier, U.; Wagner, E.
Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor cell killing
in vivo. Biomaterials 2018, 178, 630–642. [CrossRef] [PubMed]
37. Lee, J.; Saw, P.E.; Gujrati, V.; Lee, Y.; Kim, H.; Kang, S.; Choi, M.; Kim, J.I.; Jon, S. Mono-arginine
cholesterol-based small lipid nanoparticles as a systemic siRNA delivery platform for effective cancer therapy.
Theranostics 2016, 6, 192–203. [CrossRef] [PubMed]
38. Doan, C.C.; Le, L.T.; Hoang, S.N.; Do, S.M.; Le, D.V. Simultaneous silencing of VEGF and KSP by siRNA
cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells. Biol. Res. 2014,
47, 70. [CrossRef]
39. Ying, B.; Campbell, R.B. Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to
cellular models of tumor vasculature. Biochem. Biophys. Res. Commun. 2014, 446, 441–447. [CrossRef]
40. Marra, E.; Palombo, F.; Ciliberto, G.; Aurisicchio, L. Kinesin spindle protein siRNA slows tumor progression.
J. Cell Physiol. 2013, 228, 58–64. [CrossRef]
41. Brower, V. Rna interference advances to early-stage clinical trials. J. Natl. Cancer Inst. 2010, 102, 1459–1461.
[CrossRef] [PubMed]
42. Tabernero, J.; Shapiro, G.I.; LoRusso, P.M.; Cervantes, A.; Schwartz, G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.;
Infante, J.R.; Alsina, M.; et al. First-in-humans trial of an RNA interference therapeutic targeting vegf and
ksp in cancer patients with liver involvement. Cancer Discov. 2013, 3, 406–417. [CrossRef] [PubMed]
43. Bousoik, E.; Montazeri Aliabadi, H. “Do we know jack” about JAK? A closer look at JAK/STAT signaling
pathway. Front. Oncol. 2018, 8, 287. [CrossRef] [PubMed]
44. Qian, C.; Yao, J.; Wang, J.; Wang, L.; Xue, M.; Zhou, T.; Liu, W.; Si, J. ERK1/2 inhibition enhances apoptosis
induced by JAK2 silencing in human gastric cancer SGC7901 cells. Mol. Cell. Biochem. 2014, 387, 159–170.
[CrossRef] [PubMed]
45. Xu, Y.; Zhang, J.; Wu, J.; Zhong, S.; Li, H. Inhibition of JAK2 reverses paclitaxel resistance in human ovarian
cancer cells. Int. J. Gynecol. Cancer 2015, 25, 1557–1564. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
